丹红注射液联合辛伐他汀对急性冠状动脉综合征患者血脂水平和超敏C反应蛋白的影响

摘要

目的观察丹红注射液联合辛伐他汀对急性冠状动脉综合征(ACS)患者血脂水平和超敏C反应蛋白(hs-CRP)的影响.方法随机将246例ACS患者分为对照组和实验组,治疗8周,比较治疗前后血脂水平和hs-CRP变化.结果两组中血脂水平和hs-CRP均有不同程度的改变,实验组下降更明显,与对照组相比,差异有统计学意义(P<0.05).结论丹红注射液联合辛伐他汀治疗ACS患者能够显著降低其血脂水平和血浆hs-CRP,对ACS的诊治、判定预后及稳定粥样斑块等有积极意义.%Objective To observe Danhong injection combined with simvastatin lipid levels and high-sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Method 246 patients with ACS randomly divided into a control group and an experimental group, eight weeks of treatment, comparing the treatment of blood lipid levels and hs-CRP changes. Results The two groups in blood lipid levels and hs-CRP in varying degrees of change, the experimental group decreased significantly, compared with the control group, the difference was statistically significant (P<0.05). Conclusion Danhong injection combined with simvastatin treatment of ACS patients can significantly reduce blood lipid levels and plasma hs-CRP, the diagnosis and treatment of ACS, determine prognosis and stable atherosclerotic plaques positive significance.